on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG's Cold Plasma Lung Study Gains Acclaim
Viromed Medical AG announced a notable achievement for its study on cold atmospheric plasma application in the lungs. This study has recently been accepted for publication by a leading international medical journal. The research, conducted under the guidance of Prof. Dr. Hortense Slevogt from Hannover Medical School and Helmholtz Centre for Infection Research, highlights significant findings in treating severe infectious lung diseases.
The study specifically focuses on ventilator-associated pneumonia, showcasing a meaningful reduction of pathogenic germs. It reported a defined therapeutic safety window, indicating no notable tissue damage within this scope. The findings are co-authored by Uwe Perbandt, CEO of Viromed Medical AG. The scientific team plans to share more detailed insights post-publication.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news